Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Clin Lymphoma Myeloma Leuk ; 22(1): 44-51, 2022 01.
Artículo en Inglés | MEDLINE | ID: mdl-34452863

RESUMEN

BACKGROUND: We used plerixafor in 'a risk adapted approach' for stem cell mobilization for multiple myeloma (MM) patients prior to autologous stem cell transplantation (ASCT). PATIENTS AND METHODS: Between January, 2017 and December, 2019 105 consecutive patients of MM were recruited (Study Cohort). Patients received inj G-CSF 10 µg/kg in 2 divided doses for 5 days. Day 4 peripheral blood (PB) CD34+ count was used as a guide; if count was < 20 cells/µl, patients received plerixafor. For those with ≥ 20 cells/µl apheresis was commenced on day 5. We compared their outcome with 156 MM patients transplanted between 2012 and 2016 with G-CSF mobilized PB stem cells (Control Cohort). Primary end point was to collect ≥2.0  ×  106 CD34+ cells/kg (minimal harvest). Secondary end points were: no of apheresis sessions, percentage of patients with optimal stem cell harvest (≥4.0  ×  106 CD34+ cells/kg) and cost analysis. An intent to treat analysis was done. RESULT: 96.2% of patients achieved ≥ 2.0  ×  106 CD34+ cells/kg in the study cohort vs. 87.2% in the control cohort, P < .01. Mean apheresis sessions were 1.5 vs. 1.7 respectively, P < .014 . Optimal stem cell harvest was 29.5% vs. 16%,P = .23. Days for neutrophil engraftment (P < 0.025) and for IV antibiotics (P < .0017) were favorable for the study cohort. Incremental cost effectiveness ratio was $ 15.80/- and $ 10.56/- per 1% increase to achieve a minimal and optimal harvest. CONCLUSION: Plerixafor in this risk adapted strategy resulted in successful mobilization, decreased time to engraftment and was cost effective.


Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Bencilaminas/uso terapéutico , Ciclamas/uso terapéutico , Movilización de Célula Madre Hematopoyética/métodos , Mieloma Múltiple/tratamiento farmacológico , Acondicionamiento Pretrasplante/métodos , Trasplante Autólogo/métodos , Adulto , Fármacos Anti-VIH/farmacología , Bencilaminas/farmacología , Ciclamas/farmacología , Femenino , Trasplante de Células Madre Hematopoyéticas , Humanos , Masculino , Persona de Mediana Edad , Factores de Riesgo
2.
Indian J Surg Oncol ; 8(1): 46-50, 2017 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-28127182

RESUMEN

Growing teratoma syndrome, a disease characterized by presence of benign metastasis increasing in size and number after chemotherapy, is infrequent occurrence. Being unfamiliar with the disease entity, many oncologists misinterpret it as disease progression. Though the exact etio-pathognesis of the disease is still unidentified, but clinical characteristics are well defined. Being a chemo and radio-resistant disease, surgery offers only cure. We present a case of ovarian immature teratoma, who after chemotherapy presented with increased tumor size. Resected specimen confirms the diagnosis of mature teratoma leading to recognition of GTS. Surgery resulted in cure.

3.
Ann Saudi Med ; 35(1): 69-71, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26142942

RESUMEN

Renal tubular acidosis (RTA) is a disorder of renal acidification characterized by inability to acidify urine to pH < 5.5 despite the presence of severe systemic metabolic acidosis and hypokalemia. Hypokalemia leads to acute-onset paralysis and may be a presenting manifestation of RTA. Its association with various autoimmune disease has been reported previously in published reports, but has not been much emphasized. We, hereby, report a case of RTA that presented during the flare of rheumatoid arthritis (RA). A 42-year-old female, a known case of RA for 5 years, presented with persistent joint pain for 1 week and acute-onset quadriparesis for 3 days. Primary investigations revealed hypokalemia with metabolic acidosis. She was managed conservatively with potassium supplements and bicarbonate supplements along with steroids and disease-modifying anti-rheumatic drugs. Such a presentation of renal tubular acidosis in a patient during the flare of rheumatoid arthritis is distinctly rare and previously unreported in published studies.


Asunto(s)
Acidosis Tubular Renal/complicaciones , Artritis Reumatoide/complicaciones , Cuadriplejía/etiología , Acidosis Tubular Renal/tratamiento farmacológico , Adulto , Antirreumáticos/uso terapéutico , Artritis Reumatoide/tratamiento farmacológico , Femenino , Humanos , Hipopotasemia/complicaciones , Hipopotasemia/tratamiento farmacológico , Potasio/uso terapéutico , Esteroides/uso terapéutico
7.
Case Rep Rheumatol ; 2013: 923797, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23662237

RESUMEN

Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) is a rare but well-reported clinical entity. It is classically described as symmetrical involvement of both upper extremities. Asymmetrical involvement had also been reported, but unilateral presentation is very rare. We hereby report a case of unilateral RS3PE in a patient of seronegative rheumatoid arthritis which was initially misdiagnosed as cellulitis and was given high dose antibiotics without any significant improvement. Later a rheumatologic consultation leads to a prompt diagnosis, and treatment with steroids leads to dramatic reversal of symptoms. This case demonstrates the rare presentation of this rare clinical entity and highlights the necessity of awareness regarding unilateral disease to clinicians.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA